Guilford Pharmaceuticals to Host Webcast Outlining New Corporate Strategy

Guilford Pharmaceuticals to Host Webcast Outlining New Corporate
Strategy 


BALTIMORE, April 5  /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc.
(NASDAQ:GLFD) will host a webcast on April 6, 2005, beginning at approximately
12:15 p.m. Eastern Daylight Time, to outline the Company's new corporate
strategy and review results from a Phase III clinical trial of AQUAVAN(R)
Injection, a novel sedative/hypnotic in development for use in procedural
sedation.

Dean Mitchell, President and Chief Executive Officer, and William Spengler,
Executive Vice President and Chief Financial Officer will outline the Company's
new corporate strategy, financial goals and upcoming milestones. Following
their remarks, Dr. Lawrence Cohen, Associate Clinical Professor, Division of
Gastroenterology, Mount Sinai Hospital, New York, will review the results of
the Phase III AQUAVAN(R) colonoscopy trial.

To access the webcast, visit Guilford's website at
http://www.guilfordpharm.com/.  The link for the webcast is available under the
'Investor' section under 'Conferences.'  The webcast is scheduled to begin at
approximately 12:15 p.m. EDT.  An archived version of the webcast will be
available until April 20, 2005.

To listen to live audio from the webcast, dial 800-901-5241, international
callers may dial 617-786-2963.  The participant passcode is 17581864.  An audio
replay will be available beginning at approximately 2:00 p.m. April 6, 2005
until April 20, 2005.  The dial-in number for the audio replay is 888-286-8010,
international callers may dial 617-801-6888.  The passcode for the audio replay
is 84190925.

About Guilford

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the
research, development and commercialization of proprietary pharmaceutical
products that target the hospital and neurology market.  Presently, Guilford
markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with
carmustine implant), for the treatment of brain cancer, and AGGRASTAT(R)
Injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor
antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's
product pipeline includes a novel sedative, AQUAVAN(R) Injection, and drugs for
treating Parkinson's disease and post-prostatectomy erectile dysfunction.  For
additional information about GLIADEL(R) and AGGRASTAT(R), please see
http://www.guilfordpharm.com/ under Products / Marketed Products.

This press release contains forward-looking statements that involve risks and
uncertainties, including those described in the section entitled "Risk Factors"
contained in the Company's Annual Report on Form 10-K filed with the SEC on
March 7, 2005, that could cause the Company's actual results and experience to
differ materially from anticipated results and expectations expressed in these
forward-looking statements.

   Contact:  Guilford Pharmaceuticals Inc.
             Stacey Jurchison 410.631.5022
             

DATASOURCE: Guilford Pharmaceuticals Inc.



CONTACT:  Stacey Jurchison, Guilford Pharmaceuticals Inc.,

[phone], 



Web site:  http://www.guilfordpharm.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/112882.html

Copyright